Peer Reviewed

1

Document Type

Article

Publication Date

1-8-2006

Keywords

Adult, Aspirin, Body Weight, Cross-Over Studies, Dipyridamole, Dose-Response Relationship, Drug, Drug Combinations, Humans, Logistic Models, Middle Aged, Platelet Aggregation, Platelet Aggregation Inhibitors, Reference Values, Tablets, Enteric-Coated, Therapeutic Equivalency, Thromboxane B2, Treatment Outcome

Comments

This article is available at http://stroke.ahajournals.org

Abstract

BACKGROUND AND PURPOSE: Aspirin resistance may be relatively common and associated with adverse outcome. Meta-analysis has clearly shown that 75 mg plain aspirin is the lowest effective dose; however, it is not known whether the recent increased use of enteric-coated aspirin could account for aspirin resistance. This study was designed to determine whether enteric-coated aspirin is as effective as plain aspirin in healthy volunteers. METHODS: Seventy-one healthy volunteers were enrolled in 3 separate bioequivalence studies. Using a crossover design, each volunteer took 2 different aspirin preparations. Five aspirin preparations were evaluated, 3 different enteric-coated 75-mg aspirins, dispersible aspirin 75 mg and asasantin (25-mg standard release aspirin plus 200-mg modified-release dipyridamole given twice daily). Serum thromboxane (TX) B2 levels and arachidonic acid-induced platelet aggregation were measured before and after 14 days of treatment. RESULTS: All other aspirin preparations tested were inferior to dispersible aspirin (P99%) inhibition (P

Disciplines

Life Sciences

Citation

Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37(8):2153-8

PubMed ID

16794200

DOI Link

10.1161/01.STR.0000231683.43347.ec

Included in

Life Sciences Commons

Share

COinS